The drug "Onbrez Breeze": instructions for use, composition, analogs, doses

For the treatment of obstructive pulmonary disease of a chronic nature, innovative medicine "Onbrez Breezhaler" has been developed and tested for harmlessness, the photo of which is presented below.

general characteristics

This drug is produced by the Swiss company AG Novartis. There are two dosages (0.300 mg and 0.150 mg) of the drug "Onbrez Breeze". Description of the drug describes it as a white powder for inhalation, which is packaged in capsules.

This sympathomimetic inhalation agent, which treats obstructive diseases of the respiratory system. It is referred to beta2-adrenostimulyatorami selective action.

In hard gelatin capsules of the third size of a larger dose, there is a transparent, colorless lid and trunk. On the top of the black paint is the company logo, which is located below the black strip, on the bottom of the capsule there is the designation "IDL 150", which is above the black band.

In capsules of gelatin solid of the third size of smaller dose there is a transparent, colorless lid and trunk. The upper half of the logo has a blue paint, which is located below the blue strip, and on the bottom of the capsule contains a blue inscription "IDL 300", which is located above the blue strip.

Composition

One capsule contains indacaterol maleate in the amount of 0.194 mg for a smaller dose and 0.389 mg for a greater dosage. The auxiliary component in the form of sugar dairy serves as a filler, it corrects the mass of the contents.

The composition of capsules "Onbrez Breezhaler" is complex, and the instruction includes a list of all the ingredients. The coating of a smaller dose is formed by shellac, gelatin, ferric oxide of two- and trivalent black, pure water, propylene glycol.

The shell of a larger dosage of capsules includes slightly different ingredients. The coating is formed by shellac, gelatin, ferric oxide of two- and trivalent black, pure aqueous medium, propylene glycol, blue diamond pigment, titanium dioxide.

Mechanism of influence

Onbrez Breezhaler medications instructions for use describe the effect of the active ingredient indacaterol, which, as a chemical ligand, increases the response of beta2-adrenoreceptor receptors. This pharmacological effect is due to the activation of the adenylcyclase enzyme within the cells, in which the transition of adenosine triphosphate molecules to the cyclic 3 ', 5'-adenosine monophosphate form is accelerated.

The increase in the latter component causes a weakening of the musculature smooth in the bronchi. Indacaterol is highly active against beta2 receptors. Its selectivity is similar to that of formoterol.

Onbrez Breezhaler Capsules, when inhaled, exhibit a local bronchodilator effect in the respiratory system.

Its role is interrelated with a reduction in the overgrowth of pulmonary walls with an average or severe condition of obstructive disease, in the static and dynamic position of the body.

One-time daily administration leads to a permanent significant improvement in the parameters of the respiratory organs. The active substance starts to act quickly and after 10 minutes its activity is manifested. This is much more effective than the effect of salbutamol at a dose of 0.200 mg or salmeterol / fluticasone at a dosage of 0.050 / 0.500 mg. The maximum activity of indacaterol is possible after 3-4 hours from the administration of inhalation. Morning or evening use of the drug does not change its bronchodilator effect.

What heals

The drug "Onbrez Breezhaler" instruction for use advises to use for supporting bronchodilator therapy of obstructive changes in the pathways of the respiratory system to patients with pulmonary obstructive disease of a chronic nature. As a result of this disease, the air flow is limited, the amount of air inhaled decreases, and breathing difficulties develop. The initial stage of the disease can be determined by coughing, spitting, dyspnoea and hoarseness during exercise.

How to use

On the drug "Onbrez Breeze" the methods of application and dose for adults are described in the instructions. Typically, doctors recommend a one-day inhalation of the contents of one capsule with a dosage of 0.150 mg. The procedure is carried out with the help of an inhaler or breezhaler, it goes as a supplement to the medicine. Dosage can be increased only by medical prescription.

In severe form of obstruction of the lungs, one inhalation per day of the capsule with a dose of 0.300 mg. The procedure is carried out using a breeze. The maximum daily amount of the drug is equal to 0.300 mg.

Onbrez Breezhaler medicines do not include the requirements for the revision of dosage for elderly patients. Inhalations are not suitable for children, they are prescribed only after 18 years of age.

If the disease is combined with a failure of liver and renal function in a mild or moderate form, then the dosage adjustment is not performed. In cases of severe disruption of the work of the above-mentioned organs, medication is not administered.

For the drug "Onbrez Breeze", the methods of use are limited to inhalation administration by a breeze-maker of the same firm. Capsule preparation is not suitable for swallowing. It must be used daily in a certain time period. If there is a break in treatment, then the subsequent administration is carried out at the set hours of the next day.

In each pack of Onbrez Breezhaler, a device for inhalation and packaging is contoured, containing capsules with powdered contents. The medicine is equipped with a mouthpiece, a screen, a lid, a base and a button of the device for piercing.

Before the manipulation with the inhaler, remove the lid. To open the device hold its lower part, then divert the mouthpiece in the direction.

One capsule is removed from the package, hands must be dry. Then it is inserted into the inhaler, putting it in the allotted zone. Do not put the medicine inside the mouthpiece. The device closes with a characteristic click.

The next step is puncturing the capsule. For this purpose, a one-time pressing of the two piercing buttons is performed vertically. Usually you hear a snap sound, which indicates a puncture of the capsular coating. Then press both buttons on the inhaler device.

The device is considered ready for manipulation and can be used. At the beginning of the application, before entering into the mouthpiece mouth, the patient breathes deeply the air. Then he puts the tube in the mouth, holding it tightly with his mouth. Brizhaler keep one upper limb and conduct quick, uniform and deep inhalation of air. Do not touch the piercing equipment buttons.

When performing the manipulation, you hear a characteristic rattling, which is obtained by rotating the shell and then spraying the contents. The patient develops a sweet taste in the oral cavity. The absence of the desired sound signal requires the inhaler to be unpacked to check the capsule. It is not ruled out that it is stuck in the place of implementation. If a failure occurs, the capsule is removed by tapping the base of the device lightly. Do not press the side buttons again. When several capsules are pierced, they can break down.

During inhalation, the appearance of a characteristic sound is possible, in this state the patient holds his breath for the time necessary to draw the mouthpiece out of the mouth. Only then the air is exhausted. This is necessary to prevent an unpleasant sensation. Do not blow into the handset of the device.

To check the presence of powder inside the capsule, the person should lift the lid and look into the inhaler. When you see that the capsular content is large enough, then close the device and repeat all the above points for its preparation for manipulation. That the capsule is completely freed, one or two injections of the drug are enough.

Conducting inhalations can provoke a sharp attack of cough. The reason for this condition is the receipt of a full dose of the drug. Sometimes it is possible to get a small amount of powder from the capsule into the oral cavity. Both violations should not serve as an excuse for excitement.

After the inhalation, the patient needs to open the device, to do this, deflect the mouthpiece, take out the shell of the empty capsule and discard it. Then lower the mouth tube and close the lid. It is forbidden to throw an empty capsule inside the device, rinse and unwind it.

When using a new package, do not use an old inhaler. To store the packaging with the device and blisters, only a dry place is suitable.

On the drug, "Onbrez Breezhaler," the instruction recommends keeping records of the manipulations carried out using a calendar for marks, which is marked on the inner surface of the pack. When filling it, a person will remember that the next inhalation is necessary.

For weekly cleaning of the device, it is necessary to wipe the surface of the outer and inner mouthpiece using a clean dry cloth. Do not use liquid for cleaning. All parts of the inhaler should be dry.

Features of treatment

Medications "Onbrez Breezhaler" instructions for use does not contain recommendations for use in patients with asthma. This is explained by the lack of information that would prove effective and safe introduction to such people.

The implementation of inhalation may be accompanied by hypersensitivity. When allergic processes associated with difficult breathing or swallowing, edema of the tongue, lips and facial part of the head, rash in the form of urticaria, treatment should be abandoned and carry out the opposite measures.

Carrying out inhalation with medication can provoke a spasm of the bronchial tubes of a paradoxical type, which carries a danger to the life of the patient. The slightest signs cause an urgent cancellation of the medication and use of the medicine to eliminate the attack.

The drug "Onbrez Breeze" can aggravate the course of the disease, which is why it is not used as urgent measures in the early stages of acute bronchospasm. If the condition of the patient with obstruction of the lungs as a result of inhalation of the drug worsened, then a reassessment of the patient's well-being and the way of his treatment is carried out. Exceeding the maximum daily dosing is simply unacceptable.

If a severe attack develops (obstructive and asthmatic), the patient needs urgent hospitalization and resuscitation. Intensive therapy should begin as soon as possible. For drug treatment, adrenaline, corticosteroids, and euphyllin are suitable.

The medication in the form of inhalations with the recommended dosing often does not contribute to a significant effect on the work of the cardiovascular system, its effect is similar to the substances that cause the response of beta2-adrenergic receptors. It is very necessary to carry out manipulations for people with myocardial and vascular diseases, including coronary insufficiency, changes in cardiac rhythm and high blood pressure, convulsive attacks and thyrotoxicosis. Caution is also needed in case of a non-identical response to the effect of substances that cause the response of beta2-adrenoreceptor elements.

The drug is able to significantly reduce the level of potassium ions in the blood, thereby causing the development of harmful processes in the work of the heart and blood vessels. Such a decrease in K ⁺ in plasma is considered temporary, not requiring its replenishment. In severe forms of bronchial obstruction and hypokalemia, oxygen deficiency develops. Treatment of hypoxia can lead to cardiac arrhythmia.

Inhaled injection of a high dose of the drug sometimes increases the glucose level in the blood. In this regard, careful monitoring of plasma sugar concentration for people with diabetes is recommended. To protect yourself from hyperglycemia, do not use medication frequently and in high doses.

About the medicine "Onbrez Breezhaler" opinion of experts shows poor compatibility of the drug and agonists of the sites of beta2-adrenergic receptors with long exposure.

This tool treats only obstructive changes in the pathways of the respiratory system in a chronic form. In case of misuse of the medication, for example, with asthma of the bronchial type, there is a danger of the emergence of complex reactions in which the patient is hospitalized and inuabated.

There are no clinical data that would characterize the action of indacaterol on the process of bearing a child in the presence of chronic obstruction of the lungs. What potential influence it has on the human body is unknown. Women in the situation should be treated with this drug when it is necessary to obtain the expected benefit for the mother's organism, which exceeds the possible danger for the future child. Like other beta2-adrenoreceptor agonists, the drug relaxes the smooth muscles in the uterus, which affects the force of labor.

There is also no information on the ingestion of indacaterol or its metabolites into the composition of breast milk. There are data on the ingestion of substances of active action, as well as inhalation agents beta2-adrenergic in the mammary glands, which suggests the need to abolish the drug Onbrez Breezhaler for breastfeeding.

Under the influence of the medicine there is no change in the fertility of the male and female, which is proved by studies of the reproductive system.

The drug is able to influence the management of transport or to work with complex mechanisms, as it causes attacks of dizziness and attention disturbances.

Who can not use

Onbrez Breezhaler's medication is not recommended for use in cases of excessive sensitivity to the active ingredient, milk sugar or other additional ingredients.

Contraindicated inhalation for children up to the age of 18 years. They are not administered to patients with Lappe-lactase deficiency, galactosemia, hereditary intolerance to milk sugar and galactose molecules.

Onbres Brizhaler: reviews of doctors

He is considered one of the newest medications for basic use in obstructive pulmonary disease. There is a large amount of evidence for the effective and safe use of indacaterol. This tool is included in the GOLD program, which contains international recommendations for the treatment of obstructive pulmonary disease of chronic form.

Tests of clinical indacaterol were conducted with the participation of about 10,000 patients with this disease. It has been established that the active substance has a significant superiority in activity over dummies and other modern bronchodilators for the basic treatment of COPD.

On the drug " Onbrez Breeze" the doctors' testimonies testify to its ultra-long-lasting effect with a single daily intake. The drug provides rapid bronchodilator efficacy after five minutes after the end of the manipulation.

Also for Onbrez Breezhaler, the reviews indicate a reduction in the incidence of worsening in patients with lung obstruction. If the condition worsens, the attack quickly progresses, the patient is put in a hospital, a fatal outcome may occur. Hospitalization requires large financial costs.

Being a modern drug for COPD therapy, its active substance enters the lungs due to inhalation during inhalation, which is carried out with a pocket device. The medicine causes relaxation of smooth muscles in the bronchi, which contributes to their rapid expansion. This high efficiency reduces the symptoms of the disease. So from dyspnea, you can get rid of after 30 days from the beginning of manipulation. That is why the "Onbrez Breezhaler" capsules deserve positive feedback. The use of the drug allows the sick person to be active and lead a normal and full life.

Patient's opinion

On the tool "Onbrez Breezhaler" reviews of people with obstructive pulmonary disease in chronic form, prove the effectiveness of inhalations. After 5 days of use, many patients noticed a decrease in dyspnea, and after the course of treatment people began to withstand the load, almost without gasping.

You can hear negative feedback on Onrez Brizhaler capsules. They are associated with the appearance in some patients of clinically significant cardiovascular effects. These include increased heart rate and high arterial pressure. In this case, the withdrawal of treatment by this means is required.

Analogues

The Onbrez Breezhaler medication is topped by the rating of bronchodilators of the basic action. It has better efficacy compared with drugs based on salmeterol, formoterol and tiotropium.

The drug "Spiriva" is considered an analogue of the Swiss drug. It contains tiotropium bromide, which is used as an anti-asthmatic component. It is available in the form of capsules with powdered contents for inhalation at a dosage of 0.018 mg. In a pack of them contains 30 pieces, to which an inhaler is attached.

Another similar means is the preparation "Salmetol" in the form of a dosed aerosol for inhalation. One dosage contains 0.025 mg or 0.050 mg of salmeterol. Refers to bronchodilators, selective beta2-adrenergic action.

A selective action agonist for β2-adrenoreceptors is Formoterol in the form of a powder for inhalation, which is packaged in capsules. The drug treats bronchial obstruction in obstructive pulmonary disease, bronchospasm in asthma, with allergy to cold air or physical exertion.